Grants for Special district governments - Health

Grant Program: EC-SDC Grant Program for OTM / Non-Profit NN Systems Funding Organization: Wisconsin Department of Natural Resources (DNR) Contact Information: - Application Questions: DNRECSDCGrants@wisconsin.gov - Technical Program Coordinator: Briana Harter, Briana.Harter@wisconsin.gov, (608) 893-0709 Program Intent: The EC-SDC Grant Program aims to provide financial assistance to Other-Than-Municipal (OTM) and non-profit Non-Transient Non-Community (NN) public water systems serving small or disadvantaged communities in addressing emerging contaminants, specifically PFAS and manganese. Eligibility: 1. Applicants must be the owner or authorized representative of an OTM or non-profit NN public water system. 2. The public water system must serve a community with a population less than 10,000. 3. The public water system must have either PFAS or manganese contamination. Project Eligibility: Projects must include actions to address PFAS or manganese contamination. Eligible items include project planning and design, technical assistance, construction or treatment to address contamination (such as consolidation with another water system, new well construction and old well abandonment, and treatment installation). Application Process: 1. Review the eligibility requirements and grant announcement. 2. Develop your project plan, considering technical assistance if needed. 3. Complete all application materials once they become available on Jan. 16, 2024. 4. Submit the application materials and required documents to DNRECSDCGrants@wisconsin.gov. 5. The DNR will review complete applications and attachments. 6. If approved for a grant award, the DNR will notify you. 7. Reimbursement requests can be submitted quarterly for eligible expenses incurred. Deadlines: Application period opens on Jan. 16, 2024. Application period deadline: July 31, 2024. Funding: Eligible projects may receive funding up to $240,000 per public water system. $3 million is allocated for eligible PFAS projects, and $1 million for eligible manganese projects. Grant award payments are made on a reimbursement basis. Reimbursement Materials: Materials will be available once

This funding opportunity supports innovative research projects that aim to improve health outcomes through the equitable use of genomics, particularly for underrepresented populations in the U.S.

This funding opportunity supports educational programs that provide research experiences and mentoring to enhance the participation of diverse individuals in the scientific workforce related to hearing and communication disorders.

HRSA-25-002, HRSA-25-003, and HRSA-25-004 announces the opportunity to apply for funding under Ryan White HIV/AIDS Program (RWHAP) Part C Early Intervention Services (EIS) Program: Existing Geographic Service Areas. The purpose of this program is to provide comprehensive primary health care and support services in an outpatient setting for low-income people with HIV. Under this announcement, successful applicants must provide: (1) counseling for individuals with respect to HIV; (2) targeted HIV testing; (3) periodic medical evaluations of individuals with HIV and clinical and diagnostic services for HIV care and treatment; (4) therapeutic measures for preventing and treating the deterioration of the immune system, and for preventing and treating conditions arising from HIV; and (5) referrals for people with HIV to appropriate providers of health care and support services. These services are to be provided directly or through referrals, contracts, or memoranda of understanding (MOUs). This competition is open to current RWHAP Part C EIS recipients and new organizations proposing to provide RWHAP Part C EIS funded services in the geographic service areas listed in Appendix C. Please note that there are 3 funding announcement numbers included in this document with 3 different periods of performance (See Appendix C). If you are applying for more than one service area, you must submit a separate application for each proposed service area. All allowable services must relate to HIV diagnosis, care, and support, and must adhere to established HIV clinical practice standards consistent with U.S. Department of Health and Human Services (HHS) Guidelines. Please refer to the HIV/AIDS Bureau (HAB) Policy Clarification Notice (PCN) 16-02 Ryan White HIV/AIDS Program Services for a list of RWHAP allowable core medical and support services and their descriptions. According to the RWHAP Part C statute: At least 50 percent of the amount received under the award must be expended on EIS costs (except counseling and referrals/linkage to care); At least 75 percent of the award (after reserving amounts for administrative costs, planning/evaluation, and clinical quality management (CQM)) must be expended on core medical services costs (Please note: EIS is a subset of this 75 percent of the award) and; Not more than 10 percent of the total RWHAP Part C award funds can be expended on administrative costs. Applicants seeking a waiver to the core medical services requirement must submit a waiver request with this application as Attachment 15. For more details, see Program Requirements and Expectations.

This funding opportunity supports the development of standardized data elements for Alzheimer’s Disease and related dementias research, inviting applications from universities, nonprofits, and other organizations to enhance data sharing and collaboration in the field.

This funding opportunity supports multidisciplinary research centers focused on understanding and improving the transmission of seasonal influenza viruses, inviting applications from a wide range of organizations, including universities, nonprofits, and government entities.

This funding opportunity provides financial support to various organizations working to strengthen public health systems in Kenya, focusing on preventing and responding to health threats and improving overall health security.

This funding opportunity provides additional financial support for early-stage cancer researchers who have made significant progress in their work, allowing them to extend their research efforts and move towards greater independence in their scientific careers.

This funding opportunity supports educational and mentorship programs that encourage undergraduate and post-baccalaureate students from diverse backgrounds to pursue careers in genomics research.

This funding opportunity announcement (FOA) invites research projects that seek to explain the underlying mechanisms, processes, and trajectories of social relationships and how these factors affect outcomes in human health, illness, recovery, and overall wellbeing. Types of projects submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical and/or behavioral outcomes in humans to understand fundamental aspects of phenomena related to social connectedness and isolatedness. NIH considers such studies as prospective basic science studies involving human participants that meet the NIH definition of basic research and fall within the NIH definition of clinical trials (see, e.g., NOT-OD-19-024) Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applications proposing studies that include but not limited to model animal research or observational studies involving humans should submit under the companion Clinical Trials Not Allowed version of this FOA.

This funding opportunity supports researchers investigating new and existing risk factors for liver cancer, focusing on population-based studies to improve understanding and prevention of the disease in the U.S.

This funding opportunity provides substantial financial support to state and local public health agencies to modernize their operations, expand their workforce, and improve data systems, ultimately enhancing public health services and addressing health disparities.

The purpose of this funding opportunity announcement (FOA) is to solicit applications for pilot projects to elucidate a role for understudied proteins associated with rare diseases. Awards will support generation of preliminary data and/or tools around eligible understudied protein(s).Funding Opportunity Description Introduction The National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH), is transforming the translational science process so that new treatments and cures for disease can be delivered to patients faster. NCATS strives to develop innovations to reduce, remove or bypass costly and time-consuming bottlenecks in the translational research pipeline in an effort to speed the delivery of new drugs, diagnostics and medical devices to patients. This funding opportunity announcement (FOA) aims to promote innovative research to increase knowledge of understudied proteins associated with rare diseases. The submission of small research grant (R03) applications is encouraged from institutions and organizations proposing projects leading to a better understanding of eligible proteins listed below. Small research (R03) grants provide flexibility for initiating discrete, well-defined projects that realistically can be completed in one year and require only limited levels of funding. This program supports different types of projects including, but not limited to, the following: Pilot or feasibility studies; Small, self-contained research projects; Development of research methodology; and/or Development of assays to support compound screening projects; Development of human cell or animal based models. These awards will support generation of preliminary data and tools around eligible understudied protein(s) with the intent of elucidating the function of these proteins in the context of rare disease and obtaining sufficient preliminary data and/or research resources for subsequent grant applications and/or drug discovery projects. These grants are non-renewable. This Funding Opportunity Announcement does not accept applications proposing clinical trial(s). Background The human genome has revealed a great deal about the human proteome, though significant portions of the genome remain understudied. Only a subset of expressed proteins demonstrates the requisite properties to serve as targets for the development of therapeutics. Many bona fide drug targets likely remain to be studied in the Druggable Proteome (DP), which can be defined as the fraction of proteins which have the ability to bind drug-like molecules. The term "drug-like" refers to the physical, biochemical, and pharmacological attributes of small molecule compounds that are generally recognized to be required for efficacious clinical drugs in humans. While the number of proteins in the DP is upwards of 4,500, the existing clinical pharmacopeia is represented by only a few hundred targets, leaving a huge swath of druggable biology unexploited. The expanded exploration of the relationship between the protein and the rare disease phenotype, or the development of a useful tool or reagent can accelerate research into a previously understudied protein. Many interesting and critical biological processes and potential therapeutic avenues remain unexplored because an initial catalyzing event (e.g., association with a biologic process or phenotype, creation of tools or reagents for the protein, etc.) has not yet occurred. The purpose of this FOA is to spark such catalyzing events through the support of small R03 awards to identify novel drug targets for the treatment of human disease, specifically rare disease Objectives and Scope The goal of this specific solicitation is to provide a needed opportunity for the collection of preliminary data around the role of understudied proteins associated with rare diseases. This FOA will provide funding to support research that will characterize new targets for treatment of human disease among the understudied proteins of the Druggable Proteome. These projects should be carried out in a short period of time with limited resources as defined by the funding mechanism. It has been recognized through workshops and publications that understudied proteins become illuminated when (1) there are tools to study the protein (e.g., tools that modulate protein activity) and/or (2) there is biochemical, cellular, or animal model evidence of disease/physiological relevance. This FOA was developed to address the need for expanded research and validation experiments on eligible understudied protein(s), with the intent of producing preliminary data to address the lack of biochemical, cellular, or animal model data associated with many understudied proteins. It is expected that the award will be used to obtain preliminary data and/or research resources for subsequent grant applications and/or drug discovery projects. The NIH supports research on a broad range of diseases that are defined as rare; that is diseases affecting fewer than 200,000 individuals in the United States (per the Rare Disease Act of 2002). Collectively, there are an estimated 7,000 rare diseases, which affect approximately 25-30 million people in the United States. Most are serious or life-threatening, with a disproportionate number of rare diseases affecting children. At this time, effective treatments are available for fewer than 5%. The IDG Program has linked over 6,000 proteins to rare diseases, with over 80% of these proteins considered extremely understudied. For the purposes of this FOA, eligible proteins are those that have an association with rare disease through data mining of the encyclopedia of rare disease annotations for precision medicine (eRAM) and Orphanet, are considered understudied (those proteins that lack small molecule binders and/or have limited biological characterization) and are within a protein family that is traditionally considered druggable.

This grant provides funding to organizations in Northeast Georgia that work to prevent childhood trauma and promote resilience among young people from birth to age 26.

The NIH Research Education Program (UE5) supports research education activities in the mission areas of the NIH. The overarching goal of this UE5 program is to support educational activities that encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in computational genomics and data science research. To accomplish the stated over-arching goal, this NOFO will support creative educational activities with a primary focus on: Courses for Skills Development Specifically, this UE5 program will support faculty members at minority-serving institutions (MSIs) to create undergraduate or masters degree courses in computational genomics, data science, or a combination of these topics. Support for this activity will be provided by the Educational Hub for Enhancing Diversity in Computational Genomics and Data Science, created through RFA-HG-22-002. For developing skills in computational genomics and data science, these courses will leverage the resources of NIH cloud computing platforms such as NHGRIs AnVIL and the All of Us Researcher Workbench.

This grant provides funding for researchers and institutions to develop advanced imaging and biomarker technologies that improve the early detection of aggressive cancers and precancerous lesions, ultimately enhancing patient outcomes and clinical decision-making.

This funding opportunity supports innovative community-based projects aimed at reducing health disparities related to dementia and cognitive decline among underserved populations as they age.

The "Service Area Competition" grant, administered by HRSA, aims to allocate approximately $244 million to up to 88 organizations to continue providing affordable, comprehensive primary health care services to underserved communities in the U.S., with a focus on vulnerable populations, from May 2025 to April 2028.

This grant provides funding and support for underrepresented clinical scientists to develop their research skills in cancer-related fields, with a focus on addressing health disparities and preparing them for future research funding opportunities.

This funding opportunity provides financial support for early-career researchers from underrepresented backgrounds to lead independent clinical trials and develop their research skills under the mentorship of experienced scientists.